| Literature DB >> 22218754 |
Qulsum Akhter1, Akbar Masood, Ruhi Ashraf, Sabia Majid, Sabah Rasool, Tanzeela Khan, Tabasum Rashid, A Syed Sameer, Bashir Ahmad Ganai.
Abstract
Leptin is a protein hormone, mainly synthesized in adipocytes, that regulates the food intake and energy expenditure of the body. Rare mutations in the leptin gene cause obesity. Common polymorphisms of the leptin gene have been associated with obesity, however their association with arterial blood pressure has not been fully elucidated. The aim of the present study was to examine the effect of variants in the 3' flanking region of the leptin gene on blood pressure in hypertensive subjects with high (35.2 ± 5.12) and low (20.13 ± 1.3) body mass index (BMI). Microsatellite polymorphisms and the C538T SNP in the 3'UTR of the leptin gene were screened in 362 subjects, and different biochemical and anthropometric parameters were measured. The levels of serum urea, creatinine, glucose, cholesterol, triglyceride, leptin and angiotensin II were determined in all subjects. A strong association of microsatellite polymorphisms with essential hypertension was found in subjects with a high BMI, but this association was only slight in subjects with a normal BMI. The C538T variant was not found in this population. The frequency of the Class I/Class I and Class I/Class II genotype for tetranucleotide polymorphisms was also significantly higher in the hypertensive compared to the normotensive group (p ≤ 0.0001). In addition, a significant correlation was found between serum leptin and Class I/I and Class I/II genotypes. Linear regression analysis showed an independent correlation of leptinemia with BMI (p=0.019), while a notable correlation was found between serum leptin concentration and angiotensin II. The study confirmed that shorter alleles of microsatellites in the 3' flanking region of leptin are significantly associated with hypertension, however, the underlying mechanism remains unknown.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22218754 PMCID: PMC3493089 DOI: 10.3892/mmr.2012.743
Source DB: PubMed Journal: Mol Med Rep ISSN: 1791-2997 Impact factor: 2.952
Anthropometric and laboratory data of the study subjects.
| Variables | Hypertensive lean | Hypertensive obese | Normotensive obese | Normotensive lean | Sign. of difference |
|---|---|---|---|---|---|
| Age (years) | 53.00±8.35 | 50.00±8.35 | 43.20±8.60 | 42.025±8.60 | p=0.0001 |
| BMI (kg/m2) | 22.10±2.80 | 35.20±5.12 | 29.50±3.20 | 21.850±1.01 | p=0.0001 |
| Systolic blood pressure (mmHg) | 144.51±16.01 | 145.10±15.21 | 120.90±2.20 | 120.500±5.75 | p=0.0001 |
| Diastolic blood pressure (mmHg) | 92.25±10.61 | 92.20±12.18 | 80.50±3.20 | 80.050±3.12 | p=0.0001 |
| Serum creatinine (mg/dl) | 0.90±0.23 | 1.05±0.22 | 0.90±0.11 | 0.920±0.25 | p=0.4230 |
| Urea (mg/dl) | 25.75±9.39 | 30.00±6.70 | 31.00±10.50 | 26.320±8.70 | p=0.7780 |
| Cholesterol (mg/dl) | 165.00±23.80 | 175.00±23.80 | 172.00±19.80 | 160.770±25.60 | P=0.0250 |
| Glucose R (mg/dl) | 98.40±22.62 | 94.00±7.13 | 102±14 | 95.500±15.70 | p=0.5070 |
| Triglycerides (mg/dl) | 165.37±21.90 | 182.02±15.80 | 180±23 | 165±15.20 | P=0.3800 |
| Na+ | 144.00±5.10 | 141.00±6.20 | 139±5.30 | 142±8.23 | P=0.2020 |
| K+ | 4.50±0.46 | 4.03±0.48 | 4.14±0.44 | 3.900±0.56 | P=0.4100 |
| Leptin (ng/dl) | 11.90±3.77 | 18.71±15.50 | 13.82±12.63 | 9.420±12.20 | P=0.0070 |
| Angiotensin II (ng/dl) | 1.17±1.36 | 1.47±1.60 | 1.34±2.20 | 1.250±1.23 | P=0.9760 |
Values are presented as the means ± SD. P, significance between all hypertensives vs. normotensives; P2, significance between all obese vs. all lean subjects.
Linear regression analysis for all subjects (HL, HO, NL and NO), obese subjects (HO and NO), and lean subjects (HL and NL).
| Independent variables | Regression coefficients | 95% confidence interval of regression coefficient | p-value | R2 |
|---|---|---|---|---|
| BMI (HO, HL, NO, NL) | 0.255 | 0.02384 to 0.26150 | 0.019 | 0.065 |
| ANG II (HO, HL, NO, NL) | 0.171 | −0.01370 to 0.04150 | 0.120 | 0.029 |
| BMI (HO, NO) | 0.482 | −0.06166±0.01653 | 0.001 | 0.232 |
| ANG II (HO, NO) | 0.148 | −0.05043±0.05405 | 0.357 | 0.025 |
| BMI (HL, NL) | 0.167 | 0.02759±0.02397 | 0.256 | 0.028 |
| ANG II (HL, NL) | 0.203 | −0.01253 to 0.04931 | 0.235 | 0.041 |
Serum leptin was used as a dependent variable and body mass index (BMI), genotypic variant Class I/I and angiotensin II (ANG II) as independent variables. H, hypertensive; N, normotensive; L, lean; O, obese. BMI, body mass index; ANG II, angiotensin II.
Figure 2Representative gel image showing the PCR results. Lanes 1, 3 and 6 represent heterozygotes, and lanes 2, 4, 5 and 7 represent homozygotes for the Class II allele of the microsatellite polymorphism of the leptin gene. M, marker (100-bp ladder).
Frequency of the genotypes of the leptin gene polymorphism in hypertensive and normotensive subjects.
| Variants/Genotypic distribution | Hypertensive lean | Hypertensive obese | Normotensive | Total |
|---|---|---|---|---|
| C538T | ||||
| C/C | 119 | 155 | 88 | |
| C/T | Nil | Nil | Nil | 362 |
| T/T | Nil | Nil | Nil | |
| Microsatellite | ||||
| I/I | 53 (44.5) | 71 (45.8) | 12 (13.6) | 362 |
| I/II | 41 (34.4) | 60 (38.7) | 42 (47.7) | p≤0.0001 |
| II/II | 25 (21.0) | 24 (15.4) | 34 (38.6) | |
Absolute no. (percentage) of subjects are shown.
Association of different alleles with serum leptin and serum angiotensin II levels.
| Microsatellite genotypes | Serum leptin (ng/dl) | Serum angiotensin II (ng/dl) | Significance |
|---|---|---|---|
| Genotype I/I (n=26) | 19.2±6.12 | 1.2±1.35 | Pa=0.022 |
| Genotype I/II (n=34) | 18.7±15.2 | 1.40±1.55 | Pb=0.080 |
| Genotype II/II (n=24) | 16.2±12.6 | 1.28±1.26 | Pc=0.298 |
Pa and Pa1 show the significance between Class I/I vs. Class II/II of serum leptin and angiotensin II levels, respectively. Pb and Pa2 show the significance between Class I/I vs. Class I/II of serum leptin and angiotensin II levels, respectively. Pc and Pa3 show the significance between Class I/II vs. Class II/II of serum leptin and angiotensin II levels, respectively.
Figure 1Representative polyacrylamide gel image (8%) showing the results of the HpyCh4IV digested PCR product. Lanes 1–7 show the digestion pattern of different samples under evaluation [homozygous wild-type (C/C) genotypes]. Lane M shows the separation pattern of pBR322MspI digested DNA marker. C represents the undigested PCR product (control).